The development and evaluation of additional GLP-1R/GIPR dual and GLP-1R/GIPR/GcgR triple agonists are well underway for T2DM treatment, but studies in repurposing them for neurodegenerative disorders lag behind. The gene discussed is GIPR; the disease is type 2 diabetes mellitus.